A position statement by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) also recommended the use of short‐term intensive insulin (STII) for the initial management of individuals with newly diagnosed T2DM if blood glucose is more than 300 mg/dL and/or HbA1c is more than 10%–12%, especially if the patient has symptoms of hyperglycaemia (polyuria, polydipsia, nocturia) or catabolic state (weight loss or ketosis) [7]. This evidence concerns the gene INS and Hyperglycemia.